Nasdaq GlobeNewswire

DSM Sinochem Pharmaceuticals launches Caspofungin finished dosage, its first foray into the anti-fungals portfolio

Del

Rijswijk, the Netherlands, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Sustaining earlier momentum from its successful launches of generic versions of both Rosuvastatin and Atorvastatin earlier in 2018, DSM Sinochem Pharmaceuticals (DSP) has now introduced its generic Caspofungin anti-fungal drug product in the United Kingdom. Additional markets within the EU are scheduled to follow later in the year.

Caspofungin is primarily used in the treatment of invasive candidiasis and aspergillosis, along with other fungal infections. DSP’s generic version is a concentrate powder for infusion solutions, produced in the form of single use vials.

Ongoing portfolio expansion

With the launch now of its first anti-fungal finished dosage formulation, DSP is actively expanding its drug product portfolio, realizing its aspiration of becoming a full-service generics pharmaceutical company. DSP can now offer finished drug products in statins, anti-fungals and antibiotics across its global network. 

Business Unit Director for Drug Products at DSP, Lucas Wiarda stated: “With our third launch of a finished dosage drug product in 2018, I am extremely proud of the team at DSP and the successes we’ve enjoyed this year. Caspofungin is the ideal complement to our product line, which helps to move DSP forward in our goal of producing a full range of finished dosage products for our Active Pharmaceutical Ingredients (APIs).  Additionally, with Caspofungin we have a global dossier, allowing us worldwide access for production and sale in the coming years.”

With the introduction of Caspofungin finished dosage formulation into the marketplace, DSP continues to deliver on its brand promise to customers, with Quality via world-class, differentiated active pharmaceutical ingredients, Reliability through a secure supply chain for producing a finished dosage product, and Sustainability at the forefront of its drug product production, using patented enzymatic technology which ensures an unmatched eco-friendly production process.

DSP holds an electronic Common Technical Document (eCTD) dossier for Caspofungin finished dosage formulations (in 50 and 70 mg vials) requiring constant refrigerated storage between 2 and 8 degrees Celsius.

-----------------------------------------------------------------------------------------------------------------------------------

About DSM Sinochem Pharmaceuticals

DSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP develops, produces and sells intermediates, active pharmaceutical ingredients and drug products. Our employees worldwide work together to deliver cutting-edge generics solutions that help to keep customers ahead of the competition.

Headquartered in Singapore, the group has manufacturing sites and sales offices in China, India, Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company active in health, nutrition and materials, and Sinochem Group, a Fortune 500 enterprise.

For more information please visit www.dsm-sinochem.com or contact DSM Sinochem Pharmaceuticals Corporate Communications, Geoff Vokes, Senior External Communications Manager. E-Mail: geoff.vokes@dsm-sinochem.com

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Province Brands of Canada Announces Proposed Reverse Takeover of Colson Capital Corporation25.9.2018 00:56Pressemelding

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. CALGARY, Alberta, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Colson Capital Corp. (“Colson” or the “Corporation”) (TSXV: COLS.P) and Honest Inc., dba Province Brands of Canada (“Province Brands”), are pleased to announce that they have entered into an amended and restated arrangement agreement dated September 17, 2018 (the “Arrangement Agreement”) in respect of their proposed business combination transaction (the “Proposed Transaction”) which was previously announced in the news release of the Corporation dated June 5, 2018. The Proposed Transaction is expected to constitute Colson’s Qualifying Transaction under Policy 2.4 – Capital Pool Companies (“Policy 2.4”) of the TSX Venture Exchange (the “Exchange” or “TSXV”), subject to the TSXV’s approval. It is expected that the Resulting Issuer (as defined below) wil

Northland Power Opens Offshore Wind Operations Hub in Germany24.9.2018 23:30Pressemelding

New organizations support Northland’s expanded capabilities TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) today announced the opening of its offshore wind operations hub in Germany. The hub represents an expansion of Northland’s focus on offshore wind operations. Initial activities are focused on achieving synergies across the 332 MW Nordsee One wind farm, which commenced commercial operations in 2017, and the 269 MW Deutsche Bucht project, which is currently in construction. The team will also support Northland’s global project development work. Operations and maintenance activities, including remote monitoring and control of the wind turbines and substations, have been centralized in a port-side facility in the village of Norddeich. Commercial and engineering activities are being managed from a new office in the Hamburg area. “I’m pleased to welcome the Northland team to their new headquarters,” noted Troy Patton, Chief Ope

Concord Technologies Unveils NEXTSTEP—AI-driven, Cloud-based Platform that Simplifies Patient Data Capture and Document Workflows24.9.2018 23:12Pressemelding

SEATTLE, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Concord Technologies, a leading provider of cloud fax services and document process automation solutions, today launched NEXTSTEP, a new, AI-driven, cloud-based platform optimized for healthcare providers to reduce the effort required to capture, access and integrate patient health information from paper and digital documents. Concord has optimized NEXTSTEP for healthcare providers struggling to digitize document-intensive clinical workflows, though its core features apply across all highly-regulated industries. Unlike conventional systems, NEXTSTEP is pre-trained to identify, classify and extract specific, field-level data, so it saves providers the cost and effort to “teach” the system what to look for. It also extends automated document classification and routing with the ability to coordinate document handling even with frequently-changing clinical processes. “We estimate a sizable market of providers who are being underserved by conventi

The Connecticut Institute for Refugees and Immigrants honors Ethan Allen’s Farooq Kathwari24.9.2018 23:00Pressemelding

DANBURY, Conn., Sept. 24, 2018 (GLOBE NEWSWIRE) -- The Connecticut Institute for Refugees and Immigrants (CIRI) honored Farooq Kathwari, Chairman, President and CEO of Danbury-based Ethan Allen Interiors Inc., with its Legacy Award at a gala dinner in Westport, CT., on September 23. He was chosen for this honor in recognition of his commitment to humanitarian causes, to justice and human dignity, and to the plight of displaced people across the world. Mr. Kathwari has served in numerous capacities at many nonprofit organizations; among them, he is currently a member of the Board of Overseers of the International Rescue Committee, and a chairman emeritus of Refugees International. The gala commemorated CIRI's 100 years as the state’s leading champion for refugees, immigrants, survivors of torture, and survivors of human trafficking. Founded in 1918 as the International Institute of Connecticut (IICONN), CIRI remains the state’s preeminent provider of advocacy and high-impact services th

Constellation Brands Elects Jennifer M. Daniels of Colgate-Palmolive Company to its Board of Directors24.9.2018 22:07Pressemelding

VICTOR, N.Y., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today the election of Jennifer M. Daniels, chief legal officer and secretary of Colgate-Palmolive Company, to serve as a member of its board of directors, effective as of the close of business on September 20, 2018. This election increases the size of Constellation’s board from 11 to 12 members. “We are pleased to welcome Jennifer to our board of directors,” said Constellation’s Chairman of the Board Richard Sands. “Jennifer brings extensive experience in consumer product goods, mergers and acquisitions, regulatory compliance and corporate governance that will serve as tremendous assets to our board at a very exciting time as our company explores new avenues of growth, while continuing to build momentum for our high-performing beverage alcohol business.” Since November 2014, Daniels has served as chief legal officer and secretary of Colgate-Pa

World Conference on Lung Cancer Monday Press Conference: Clinical Research Results and Gender Differences in Lung Cancer Survival24.9.2018 20:26Pressemelding

TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- At today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC), conference co-president Dr. Andrea Bezjak, M.D., FRCPC, MSc, professor in the Departments of Radiation Oncology and Health Policy, Management and Evaluation at the University of Toronto and staff radiation oncologist at Princess Margaret Cancer Centre, summarized the wide-ranging study topics presented in today’s conference, from significant clinical research findings to gender differences in lung cancer survival. IMpower132 study shows atezolizumab in combination with carboplatin and pemetrexed improves survival in Stage IV non-squamous NSCLC Recent findings from the IMpower132 study, presented by Vassiliki A. Papadimitrakopoulou, M.D., chief of the Section of Thoracic Medical Oncology at MD Anderson Cancer Center, demonstrate that the use of atezolizumab in combination with carboplatin as first-l

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom